HLA-DPB1 Mismatch Permissiveness and Activating KIR Haplotypes Have Different Impact on Allogeneic Hematopoietic Cell Transplant Survival Outcomes in Acute Leukemias and Myelodysplastic Syndrome

Jerry W. Lee(Loma Linda University), Aaron C. Logan(University of California, San Francisco), Raja Rajalingam(University of California, San Francisco), Peter H. Sayre(Immune Tolerance Network), Weiyun Z. Ai(City College of San Francisco), Thomas G. Martin(University of California San Francisco Medical Center), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Rebecca L. Olin(University of California, San Francisco), Neil Dunavin(University Medical Center), Catherine C. Smith(University of California, San Francisco), Denice Kong, Karin Gaensler(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco)
Transplantation and Cellular Therapy
February 1, 2023
10.1016/s2666-6367(23)00373-1
Cited by 0

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782